Well-Established Independent Pharmacy, Texas Metro

$20.9M

Revenue

$1.3M

SDE

3.0x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is an established independent pharmacy operating in a Texas metropolitan market, generating roughly $20.9M in annual revenue and $1.27M in EBITDA. The business fills prescriptions for a recurring patient base and likely carries the standard mix of retail front-end sales, third-party insurance reimbursement, and possibly specialty or compounding revenue lines that lift margins above a pure retail script model. At a $3.75M asking price against $1.27M EBITDA, the deal is priced at roughly 2.95x, which is a reasonable entry point for a healthcare cash-flow business.

Pharmacies are among the more defensive small-business models an acquirer can own. Patients on maintenance medications refill month after month regardless of the economy, and a well-run store builds sticky relationships with prescribers, insurers, and repeat customers. The recurring nature of prescription refills produces predictable, contract-like revenue that is far more durable than discretionary retail.

The caveat is margin structure. A 6.1% EBITDA margin on $20.9M in revenue is typical for a pharmacy dominated by third-party reimbursement, where reimbursement rates, DIR fees, and PBM contracts dictate profitability. The quality of this deal hinges on the mix between low-margin insurance scripts and higher-margin cash, compounding, or specialty business, and on how exposed the store is to reimbursement compression.

Why we like it

Earnings quality is anchored in recurring prescription refills, where maintenance medication patients return monthly by default rather than needing to be re-won. At $20.9M revenue and $1.27M EBITDA, the cash flow is real and the 2.95x multiple leaves room for a levered return without heroic assumptions.
Durability comes from the essential nature of the product. People fill prescriptions in every economic environment, and an established store in a desirable Texas metro carries prescriber relationships and patient loyalty that are difficult for a new competitor to replicate quickly.
Market tailwinds favor pharmacies serving aging populations and chronic-condition patients, both of which are growing in Texas metros. Independent pharmacies that survive PBM pressure often win share as chain locations close in certain neighborhoods.
The operator advantage is meaningful because pharmacy profitability is driven by mix and cost discipline. An owner who can push cash-pay compounding, immunizations, adherence programs, and front-end margin can expand the 6.1% EBITDA margin without needing more scripts.

How to improve it

Audit the payer and product mix in the first 30 days to identify the split between third-party reimbursement scripts and higher-margin cash, compounding, and specialty revenue. Shifting even a modest share of volume toward cash-pay lines directly expands the thin 6.1% margin.
Renegotiate or optimize PBM and wholesaler contracts, since reimbursement rates and DIR fees are the single largest lever on pharmacy profitability. Benchmark generic drug purchasing against secondary wholesalers to capture spread on high-volume SKUs.
Launch or expand clinical services such as immunizations, medication therapy management, and adherence packaging. These carry better margins than dispensing and deepen patient stickiness, raising retention across the recurring refill base.
Build a medication synchronization and refill reminder program to lock in the monthly refill cadence. Higher adherence increases script counts per patient and stabilizes the recurring revenue that underpins the entire valuation.
Grow the front-end retail and durable medical equipment offerings where local competition is weak. Front-end gross margins are materially higher than dispensing and can add incremental profit on existing foot traffic.
Evaluate delivery and long-term-care or assisted-living facility contracts to add recurring, higher-volume script channels. Institutional relationships bring predictable batch volume that smooths seasonality and lifts total throughput.

Diligence notes

Break down revenue by payer type and margin to understand how much of the $1.27M EBITDA depends on third-party reimbursement versus cash and specialty. Reimbursement-heavy pharmacies face ongoing DIR fee and PBM rate compression that can erode earnings quickly.
Verify the top prescriber and referral concentration. If a handful of physicians or a single clinic drives a large share of scripts, the loss of one relationship could meaningfully impair volume and value.
Confirm PBM contract terms, DIR fee exposure, and any pending reimbursement changes. These off-balance-sheet clawbacks and rate adjustments are often invisible in headline EBITDA and can turn a profitable store into a marginal one.
Review inventory levels, controlled substance compliance history, DEA and state board records, and any past audits. Regulatory issues, diversion problems, or failed audits are deal-killers in pharmacy and must be cleared before close.
Establish years in business, ownership structure, and reason for sale, all of which are undisclosed here. Understand whether the pharmacist-owner is transferable and whether a licensed pharmacist-in-charge stays post-close.
Analyze script count trends over the trailing three years to confirm the patient base is stable or growing rather than declining. Falling script volume masked by drug price inflation would signal an eroding underlying business.

Source

Originally listed on DealStream. View original listing →